242 related articles for article (PubMed ID: 34767764)
1. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N; Brunner HI; Synoverska O; Ting TV; Mendoza CA; Spindler A; Vyzhga Y; Marzan K; Grebenkina L; Tirosh I; Imundo L; Jerath R; Kingsbury DJ; Sozeri B; Vora SS; Prahalad S; Zholobova E; Butbul Aviel Y; Chasnyk V; Lerman M; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Posner HB; Kanik KS; Wouters A; Chang C; Zhang R; Lazariciu I; Hsu MA; Suehiro RM; Martini A; Lovell DJ;
Lancet; 2021 Nov; 398(10315):1984-1996. PubMed ID: 34767764
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Nash P; Coates LC; Fleishaker D; Kivitz AJ; Mease PJ; Gladman DD; FitzGerald O; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Kanik KS
Lancet Rheumatol; 2021 Apr; 3(4):e270-e283. PubMed ID: 38279411
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.
Brunner HI; Akikusa JD; Al-Abadi E; Bohnsack JF; Boteanu AL; Chedeville G; Cuttica R; De La Pena W; Jung L; Kasapcopur O; Kobusinska K; Schulert GS; Neiva C; Rivas-Chacon R; Rizo Rodriguez JC; Vazquez-Del Mercado M; Wagner-Weiner L; Weiss JE; Wouters C; Posner H; Wouters A; Chang C; White C; Kanik K; Liu S; Martini A; Lovell DJ; Ruperto N
Ann Rheum Dis; 2024 Jun; ():. PubMed ID: 38849152
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.
Ilowite NT; Prather K; Lokhnygina Y; Schanberg LE; Elder M; Milojevic D; Verbsky JW; Spalding SJ; Kimura Y; Imundo LF; Punaro MG; Sherry DD; Tarvin SE; Zemel LS; Birmingham JD; Gottlieb BS; Miller ML; O'Neil K; Ruth NM; Wallace CA; Singer NG; Sandborg CI
Arthritis Rheumatol; 2014 Sep; 66(9):2570-9. PubMed ID: 24839206
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis.
Chang C; Vong C; Wang X; Hazra A; Diehl A; Nicholas T; Mukherjee A
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):599-611. PubMed ID: 38298058
[TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of polyarticular juvenile idiopathic arthritis.
Webb K; Wedderburn LR
Curr Opin Rheumatol; 2015 Sep; 27(5):505-10. PubMed ID: 26147756
[TBL] [Abstract][Full Text] [Related]
8. Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis.
Navarro-Compán V; Deodhar A; Bahiri R; Bushmakin AG; Cappelleri JC; Rammaoui J
Arthritis Res Ther; 2024 May; 26(1):105. PubMed ID: 38790040
[TBL] [Abstract][Full Text] [Related]
9. Overlap of International League of Associations for Rheumatology and Preliminary Pediatric Rheumatology International Trials Organization Classification Criteria for Nonsystemic Juvenile Idiopathic Arthritis in an Established UK Multicentre Inception Cohort.
Shoop-Worrall SJW; Macintyre VG; Ciurtin C; Cleary G; McErlane F; Wedderburn LR; ; Hyrich KL
Arthritis Care Res (Hoboken); 2024 Jun; 76(6):831-840. PubMed ID: 38212149
[TBL] [Abstract][Full Text] [Related]
10. A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis.
Decker RL; Steven Ernest C; Radtke DB; Wang R; Araújo J; Keller SY; Zhang X
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):970-981. PubMed ID: 38532270
[TBL] [Abstract][Full Text] [Related]
11. Choice and switch of biologic drugs in juvenile idiopathic arthritis.
Şener S; Başaran Ö; Batu ED; Cüceoğlu MK; Balık Z; Aliyev E; Bayındır Y; Bilginer Y; Özen S
Turk J Pediatr; 2023; 65(6):980-989. PubMed ID: 38204313
[TBL] [Abstract][Full Text] [Related]
12. Application of the new PRINTO classification criteria for juvenile idiopathic arthritis in a sample of Portuguese patients.
Catarino S; Nunes J; Ganhão S; Aguiar F; Rodrigues M; Brito I
ARP Rheumatol; 2024; 3(1):11-17. PubMed ID: 38558063
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.
Brunner HI; Tzaribachev N; Cornejo GV; Joos R; Gervais E; Cimaz R; Calvo Penadés I; Cuttica R; Lutz T; Quartier P; Gandhi Y; Nys M; Wong R; Martini A; Lovell DJ; Ruperto N;
Pediatr Rheumatol Online J; 2020 Feb; 18(1):19. PubMed ID: 32087715
[TBL] [Abstract][Full Text] [Related]
14. Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches.
Oberle EJ; Harris JG; Verbsky JW
Clin Epidemiol; 2014; 6():379-93. PubMed ID: 25368531
[TBL] [Abstract][Full Text] [Related]
15. Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study.
Rebollo-Giménez AI; Rosina S; Natoli V; Burrone M; Barone P; Campus S; Civino A; Consolini R; Filocamo G; Gallizzi R; Gattinara M; La Torre F; Maggio MC; Magni-Manzoni S; Magnolia MG; Miniaci A; Montin D; Pastore S; Petaccia A; Pieropan S; Rigante D; Simonini G; Ridella F; Orsi SM; Angioloni S; Carlini L; Ruperto N; Consolaro A;
Clin Exp Rheumatol; 2024 Mar; 42(3):757-763. PubMed ID: 38147312
[TBL] [Abstract][Full Text] [Related]
16. Lung Disease: A Rare but Devastating Complication of Systemic Juvenile Idiopathic Arthritis and the Use of Tofacitinib as a Treatment.
Kaplan MM; Cinel G; Çelikel E
Arch Bronconeumol; 2024 Jun; 60(6):374-375. PubMed ID: 38402050
[No Abstract] [Full Text] [Related]
17. Beyond the guidelines management of juvenile idiopathic arthritis: a case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome.
Vukić V; Smajo A; Vidović M; Vukojević R; Harjaček M; Lamot L
BMC Pediatr; 2021 Jan; 21(1):40. PubMed ID: 33451288
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.
Khanna D; Padilla C; Tsoi LC; Nagaraja V; Khanna PP; Tabib T; Kahlenberg JM; Young A; Huang S; Gudjonsson JE; Fox DA; Lafyatis R
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35943798
[TBL] [Abstract][Full Text] [Related]
19. The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis.
Shoop-Worrall SJW; Moull L; McDonagh JE; Hyrich KL
J Rheumatol; 2022 Sep; 49(9):1037-1041. PubMed ID: 35365583
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
